XBiotech Statistics
Total Valuation
XBiotech has a market cap or net worth of $70.43 million. The enterprise value is -$45.03 million.
| Market Cap | 70.43M |
| Enterprise Value | -45.03M |
Important Dates
The last earnings date was Thursday, May 14, 2026.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
XBiotech has 30.49 million shares outstanding. The number of shares has increased by 0.05% in one year.
| Current Share Class | 30.49M |
| Shares Outstanding | 30.49M |
| Shares Change (YoY) | +0.05% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 25.09% |
| Owned by Institutions (%) | 6.78% |
| Float | 22.84M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.52 |
| P/TBV Ratio | 0.52 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 39.03
| Current Ratio | 39.03 |
| Quick Ratio | 38.60 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -25.93% and return on invested capital (ROIC) is -281.80%.
| Return on Equity (ROE) | -25.93% |
| Return on Assets (ROA) | -18.81% |
| Return on Invested Capital (ROIC) | -281.80% |
| Return on Capital Employed (ROCE) | -35.38% |
| Weighted Average Cost of Capital (WACC) | 8.88% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$461,621 |
| Employee Count | 87 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, XBiotech has paid $255,000 in taxes.
| Income Tax | 255,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -11.49% in the last 52 weeks. The beta is 0.84, so XBiotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.84 |
| 52-Week Price Change | -11.49% |
| 50-Day Moving Average | 2.44 |
| 200-Day Moving Average | 2.47 |
| Relative Strength Index (RSI) | 36.29 |
| Average Volume (20 Days) | 28,448 |
Short Selling Information
The latest short interest is 181,275, so 0.59% of the outstanding shares have been sold short.
| Short Interest | 181,275 |
| Short Previous Month | 184,007 |
| Short % of Shares Out | 0.59% |
| Short % of Float | 0.79% |
| Short Ratio (days to cover) | 7.33 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -48.41M |
| Pretax Income | -39.91M |
| Net Income | -40.16M |
| EBITDA | -46.83M |
| EBIT | -48.41M |
| Earnings Per Share (EPS) | -$1.32 |
Balance Sheet
The company has $115.46 million in cash and n/a in debt, with a net cash position of $115.46 million or $3.79 per share.
| Cash & Cash Equivalents | 115.46M |
| Total Debt | n/a |
| Net Cash | 115.46M |
| Net Cash Per Share | $3.79 |
| Equity (Book Value) | 135.02M |
| Book Value Per Share | 4.43 |
| Working Capital | 114.05M |
Cash Flow
In the last 12 months, operating cash flow was -$42.17 million and capital expenditures -$195,000, giving a free cash flow of -$42.36 million.
| Operating Cash Flow | -42.17M |
| Capital Expenditures | -195,000 |
| Depreciation & Amortization | 1.58M |
| Net Borrowing | n/a |
| Free Cash Flow | -42.36M |
| FCF Per Share | -$1.39 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
XBiotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.05% |
| Shareholder Yield | n/a |
| Earnings Yield | -57.03% |
| FCF Yield | -60.15% |
Analyst Forecast
The average price target for XBiotech is $18.00, which is 679.22% higher than the current price. The consensus rating is "Buy".
| Price Target | $18.00 |
| Price Target Difference | 679.22% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |